Longitudinal Gut Microbiome Study in Relapsing-Remitting MS Patients

In a study of 29 treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS), gut microbiota composition and diversity remained stable over one year. While there was a trend indicating that worsening disability (measured by EDSS) correlated with increased microbiome instability, this did not reach statistical significance. Additionally, GFAP levels increased significantly, while NfL levels decreased and S100B levels remained unchanged.

Tags: #GutHealth #Disability #Biomarkers #SymptomMgmt
Most relevant to: Neurologist, Immunologist
Source: Read original source (PMID 42795661)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Why it matters

This research highlights the stability of gut microbiota in RRMS patients over one year, suggesting that changes in gut microbiota may not occur as the disease progresses. Understanding the association between microbiome changes and disability could inform future studies and lead to better management strategies for MS patients.

What this does not prove

The study's exploratory analyses noted that significant associations found did not hold after adjustments for multiple testing. Moreover, the small sample size necessitates larger longitudinal studies to better understand these relationships.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Observational
Participants / samples: 29 · basis not reported
Randomised: No
Controlled: Not reported
Primary endpoint met: No
Relevant MS type: RRMS
Publication date: 2026-09-17
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Other

Original sources

Primary evidenceGut Microbiome Stability in Relapsing-Remitting MS ↗

Supporting passages (11)

study phaseThis study aimed to identify longitudinal gut microbiome changes in patients with relapsing-remitting multiple sclerosis (RRMS) and their association with disability and specific serum biomarkers, including predicted metabolic pathways.

study designIn this prospective longitudinal study, 29 treatment-naïve RRMS patients were evaluated at baseline and after one year of disease-modifying therapy.

subjectsIn the 29 patients, overall gut microbiota composition and diversity remained stable during follow-up.

sample sizeIn the 29 patients, overall gut microbiota composition and diversity remained stable during follow-up.

randomizedThis study aimed to identify longitudinal gut microbiome changes in patients with relapsing-remitting multiple sclerosis (RRMS) and their association with disability and specific serum biomarkers, including predicted metabolic pathways.

primary endpoint metAlthough EDSS progression was associated with a trend toward greater microbiome instability, this association did not reach statistical significance.

research categoriesThis study aimed to identify longitudinal gut microbiome changes in patients with relapsing-remitting multiple sclerosis (RRMS) and their association with disability and specific serum biomarkers, including predicted metabolic pathways.

relevant ms typesThis study aimed to identify longitudinal gut microbiome changes in patients with relapsing-remitting multiple sclerosis (RRMS) and their association with disability and specific serum biomarkers, including predicted metabolic pathways.

findingsoverall gut microbiota composition and diversity remained stable during follow-up

limitationsExploratory taxonomic and functional associations did not remain significant after correction for multiple testing

publication datePublication date: 2026-09-17

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.